Neoadjuvant chemotherapy plus trastuzumab in stage II/III breast cancer with low HER2 expression

被引：1
|
作者：
Khan, Qamar J.
O'Dea, Anne
Fabian, Carol J.
Connor, Carol Sue
McGinness, Marilee
Mammen, Joshua Matthew Varghise
Wagner, Jamie Lynn
Baccaray, Stella
Springer, Michelle
Yeh, Henry
Sharma, Priyanka
机构：
[1] Univ Kansas Med Ctr, Kansas City, KS USA
[2] Drieling Schmidt Canc Inst, Hays, KS USA
[3] Univ Kansas Med Ctr, Westwood, KS USA
[4] Univ Kansas, Kansas City, KS USA
[5] Univ Kansas, Olathe, KS USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.1039
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1039
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Neoadjuvant dose-dense docetaxel, carboplatinum, and trastuzumab (ddTCH) chemotherapy for HER2 overexpressing breast cancer
    Bayraktar, S.
    Bayraktar, U. D.
    Reis, I. M.
    Pegram, M.
    Welsh, C.
    Silva, O.
    Franchesci, D.
    Gomez, C. R.
    Hurley, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [32] Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer
    Natoli, Clara
    Vici, Patrizia
    Sperduti, Isabella
    Grassadonia, Antonino
    Bisagni, Giancarlo
    Tinari, Nicola
    Michelotti, Andrea
    Zampa, Germano
    Gori, Stefania
    Moscetti, Luca
    De Tursi, Michele
    Panebianco, Michele
    Mauri, Maria
    Ferrarini, Ilaria
    Pizzuti, Laura
    Ficorella, Corrado
    Samaritani, Riccardo
    Mentuccia, Lucia
    Iacobelli, Stefano
    Gamucci, Teresa
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2013, 139 (07) : 1229 - 1240
  • [33] Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer
    Clara Natoli
    Patrizia Vici
    Isabella Sperduti
    Antonino Grassadonia
    Giancarlo Bisagni
    Nicola Tinari
    Andrea Michelotti
    Germano Zampa
    Stefania Gori
    Luca Moscetti
    Michele De Tursi
    Michele Panebianco
    Maria Mauri
    Ilaria Ferrarini
    Laura Pizzuti
    Corrado Ficorella
    Riccardo Samaritani
    Lucia Mentuccia
    Stefano Iacobelli
    Teresa Gamucci
    Journal of Cancer Research and Clinical Oncology, 2013, 139 : 1229 - 1240
  • [34] Neoadjuvant pyrotinib plus trastuzumab and chemotherapy for HER2-positive breast cancer: a prospective cohort study
    Liu, Lu
    Zhu, Mingzhi
    Wang, Yanyan
    Li, Muhan
    Gu, Yuanting
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2023, 21 (01)
  • [35] Neoadjuvant pyrotinib plus trastuzumab and chemotherapy for HER2-positive breast cancer: a prospective cohort study
    Lu Liu
    Mingzhi Zhu
    Yanyan Wang
    Muhan Li
    Yuanting Gu
    World Journal of Surgical Oncology, 21
  • [36] Phase II Study of Nab-paclitaxel Plus Cyclophosphamide Plus Trastuzumab Neoadjuvant Chemotherapy in Early HER-2-positive Breast Cancer
    Ogino, Misato
    Fujii, Takaaki
    Koibuchi, Yukio
    Nakazawa, Yuko
    Takata, Daisuke
    Shirabe, Ken
    ANTICANCER RESEARCH, 2021, 41 (08) : 3899 - 3904
  • [37] HER2 and topoisomerase IIα: possible predictors of response to neoadjuvant chemotherapy for breast cancer patients
    Zhu Li
    Li Ya-Fen
    Chen Wei-Guo
    He Jian-Rong
    Peng Chen-Hong
    Zhu Zheng-Gang
    Li Hong-Wei
    CHINESE MEDICAL JOURNAL, 2008, 121 (20) : 1965 - 1968
  • [38] HER2 and topoisomerase IIα:: possible predictors of response to neoadjuvant chemotherapy for patients with breast cancer
    Zhu, L.
    Li, Y. F.
    Chen, W. G.
    He, J. R.
    Zhu, Z. G.
    Li, H. W.
    BREAST, 2007, 16 : S51 - S51
  • [39] Assessment of change in HER2 status and its outcomes after neoadjuvant chemotherapy with trastuzumab and/or pertuzumab in early-stage breast cancer patients
    Godbole, Manasi M.
    Shango, Kathren
    Meranda, Matthew
    Wilson, Carl P.
    Dabak, Vrushali
    CANCER RESEARCH, 2023, 83 (07)
  • [40] Significance of HER2 Status in Neoadjuvant Chemotherapy for Breast Cancer Patients
    Wang, Chengqin
    Xing, Xiaoming
    Chen, Zhaoxu
    Wei, Zhimin
    Li, Yujun
    LABORATORY INVESTIGATION, 2023, 103 (03) : S226 - S228
12345